The last sentence but one in the article by Rimmer, Fleming, and Kohner in this month's issue reads, 'The phenomenon of hypoxic viscosity could be important because it might present a new target for pharmacological attack.' This had a familiar ring, and I managed after some thought to recall why. I had used a somewhat similar phrase myself when writing about the possible anoxic basis for rubeosis in neovascular glaucoma: 'When pathology is understood, rational treatment may follow'.' Unfortunately the word 'may' is especially important in the foregoing sentence. One of the most frustrating things in medicine is to understand the pathology and not be able to do anything about it so far as an individual patient is concerned. Many of the inherited diseases come into this category. Killing off affected fetuses may be one way of pre-empting the problem, but it doesn't help a living patient. I see that I am wandering from my subject.
Does the paper from Rimmer and colleagues get us any further in our quest for control of diabetic retinopathy? As the paper reminds us, retinopathy is now the commonest cause of blindness in people of working age in the UK and USA. Present treatment is directed rather at the results of the retinopathy (neovascularisation and haemorrhage),2 as indeed is the treatment for rubeosis and sickle cell retinopathy.
It is of interest that it took the retinal hypoxic theory of neovascularisation, first proposed by Michaelson3 in 1948, more than 10 years to yield any fruit in the form of treatment. The first retinal ablations performed for the specific purpose of treating remote neovascularisation were not reported until 1961.4 One certainly hopes that, if other workers confirm the claim of Rimmer and colleagues to have established a working hypothesis to tie together their previous observation5 of slowing of the retinal blood flow in patients with retinopathy (by entoptic blue light studies), this will lead rapidly to advances in treatment of this damaging condition.
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